John M. Wallmark
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Ear and Head Tumors
-
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 8
- Cancer Immunotherapy and Biomarkers 5
- Lung Cancer Research Studies 2
- Cancer Treatment and Pharmacology 2
- Colorectal Cancer Treatments and Studies 2
-
- Prostate Cancer Treatment and Research 1
- Co-authors
- Sarina A. Piha‐Paul (6 shared papers)Samuel Ejadi (4 shared papers)Jean‐Pierre Delord (4 shared papers)Bhumsuk Keam (4 shared papers)Sanatan Saraf (4 shared papers)Elena Élez (4 shared papers)Christophe Massard (2 shared papers)Juanita Lopez (2 shared papers)
- Journals
- Annals of Oncology (3 papers)Journal of Clinical Oncology (2 papers)Cancer Investigation (1 paper)European Journal of Cancer (1 paper)PLoS ONE (1 paper)
- Partner nations
- United StatesSouth KoreaCanada
In The Last Decade
John M. Wallmark
11 papers receiving 766 citations
John M. Wallmark's Hit Papers
Peers
Comparison fields: 5 of 49
- Oncology 474
- Immunology 187
- Pulmonary and Respiratory Medicine 237
- Pathology and Forensic Medicine 110
- Cancer Research 66
Countries citing papers authored by John M. Wallmark
This map shows the geographic impact of John M. Wallmark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Wallmark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Wallmark more than expected).
Fields of papers citing papers by John M. Wallmark
This network shows the impact of papers produced by John M. Wallmark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Wallmark. The network helps show where John M. Wallmark may publish in the future.
Co-authors
The 25 scholars most cited alongside John M. Wallmark, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study Hit paper breakdown → | 2018 | 269 |
| 2 | 2017 | 229 | |
| 3 | 2018 | 150 | |
| 4 | 2012 | 36 | |
| 5 | 2016 | 36 | |
| 6 | Scleromyxedema: successful treatment of cutaneous and neurologic symptoms. | 2000 | 18 |
| 7 | 2015 | 16 | |
| 8 | 2016 | 11 | |
| 9 | 2014 | 5 | |
| 10 | 2019 | 4 | |
| 11 | Tamoxifen's impact on the management of breast cancer: the oncologist's perspective. | 1997 | 1 |
About John M. Wallmark
John M. Wallmark is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Pathology and Forensic Medicine and Dermatology, having authored 11 papers that have together received 775 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (5 papers), Lung Cancer Research Studies (2 papers), Salivary Gland Tumors Diagnosis and Treatment (2 papers), Cancer Treatment and Pharmacology (2 papers), Colorectal Cancer Treatments and Studies (2 papers), Estrogen and related hormone effects (1 paper), Prostate Cancer Treatment and Research (1 paper) and Systemic Sclerosis and Related Diseases (1 paper). The work is most often cited by research in Oncology (474 citations), Immunology (187 citations), Pulmonary and Respiratory Medicine (237 citations), Pathology and Forensic Medicine (110 citations) and Cancer Research (66 citations). John M. Wallmark has collaborated with scholars based in United States, South Korea and Canada. Frequent co-authors include Sarina A. Piha‐Paul, Samuel Ejadi, Jean‐Pierre Delord, Bhumsuk Keam, Sanatan Saraf, Elena Élez, Christophe Massard, Juanita Lopez, Rahul Aggarwal and Stephen J. O’Keefe. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Cancer Investigation, European Journal of Cancer and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.